We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
10
5 active
Approvals
4
Total approvals
Agencies
2
Regulatory bodies
Founded
N/A
Active, not recruiting
5
50.0%
Completed
EMA
European Medicines Agency
1
CIMA_AEMPS
Spanish Agency for Medicines and Medical Devices
3
- Orphalan has acquired Orphelia Pharma, a company specializing in rare and severe pediatric diseases in neurology and oncology, strengthening its position as a European leader in rare diseases. - The acquisition expands Orphalan's capabilities in rare neurological and oncological pediatric diseases while improving access to medicines for children and adults with rare conditions. - Orphelia Pharma brings one authorized medicine in the European Union (Kigabeq®) and a second under regulatory review (Kizfizo®) to the combined platform. - The strategic transaction creates a unique platform combining scientific excellence, agility, and global commercialization capabilities to accelerate innovation in orphan diseases.
